Form 4: Lyra Therapeutics Director W. Bradford Smith Acquires 32,000 Restricted Stock Units

Director W. Bradford Smith reports acquisition of 32,000 Restricted Stock Units in Lyra Therapeutics, Inc.

Summary

• W. Bradford Smith, a director of Lyra Therapeutics, Inc., reported the acquisition of 32,000 Restricted Stock Units (RSUs) on May 14, 2025.
• Each RSU represents a contingent right to receive one share of Lyra Therapeutics' common stock.
• The RSUs will vest 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026, or (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
• Following the transaction, Smith directly owns 32,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.

Future Outlook

The vesting of the RSUs is contingent upon future events, including the company's annual meeting date, the specified date in 2026, or a change in control.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.

Stakeholder Impact

• The acquisition of RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Lyra Therapeutics, Restricted Stock Units, RSU, Director, Beneficial Ownership, Form 4, Securities, Smith W Bradford